95298-88-7

Basic information

• Product Name: N-HYDROXY-2-METHOXY-ACETAMIDINE
• Synonyms: (1Z)-N'-hydroxy-2-methoxyethanimidamide(SALTDATA: FREE);2-Methoxyacetamidoxime;N-Hydroxy-2-methoxyethanimidamide
• CAS NO: 95298-88-7
• Molecular Formula: C₃H₈N₂O₂
• Molecular Weight: 104.11
• Mol File: 95298-88-7.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-HYDROXY-2-METHOXY-ACETAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-2-METHOXY-ACETAMIDINE(95298-88-7)
• EPA Substance Registry System: N-HYDROXY-2-METHOXY-ACETAMIDINE(95298-88-7)

Safety Data

• Hazardous Substances Data: 95298-88-7(Hazardous Substances Data)

Usage

General Description

N-HYDROXY-2-METHOXY-ACETAMIDINE is a chemical compound that is used in the pharmaceutical industry for its potential therapeutic properties. It has been studied for its ability to inhibit certain enzymes, potentially making it useful in the development of new medications. The compound contains a hydroxyl group and a methoxy group, which are known to play important roles in the reactivity and biological activity of organic compounds. N-HYDROXY-2-METHOXY-ACETAMIDINE has also been investigated for its potential antimicrobial properties, suggesting that it may have applications in the development of new antibiotics. Overall, this compound shows promise for its potential use in the development of new pharmaceuticals due to its unique structure and potential therapeutic properties.

Upstream product

• 1738-36-9 2-methoxyacetonitrile 

Downstream Products

• 274919-42-5 9-(3,5-dinitrobenzyl)-3-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-9H-β-carboline 
• 936239-89-3 (2E)-1-methoxyacetone O-(4-nitrobenzoyl)oxime 
• 1204301-38-1 4-[(R)-3-(4-methanesulfonylphenoxy)-1-methylpropyl]-1-(3-methoxymethyl-[1,2,4]oxadiazol-5-yl)piperidine 
• 1383575-36-7 2-(3-(methoxymethyl)-1,2,4-oxadiazol-5-yl)benzyl benzoate 

Relevant articles and documents

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

The present invention relates to compounds of the formula (I), wherein R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.